Nav: Home

The inflammation connection

April 01, 2019

Scientists at the Centre for Genomic Regulation (CRG), part of the Barcelona Institute of Science and Technology (BIST), in Barcelona, Spain, have uncovered the biological details of how cells produce a crucial molecule involved in inflammation, pointing towards a new avenue for the development of anti-inflammatory drugs. The findings are published this month in the journal Developmental Cell.

The team's research, led by Vivek Malhotra, ICREA Research Professor and head of the Intracellular Compartmentation group at the CRG, focuses on IL-1β, a protein released by immune cells in response to 'danger' signals such as bacterial infection or tissue damage, triggering inflammation that helps to fight off infection and aids healing.

Excessive production of IL-1β leads to unwanted inflammation, which has been implicated in a wide range of illnesses including auto-immune, neurodegenerative and cardiovascular diseases. Making sure that IL-1β is produced at the right time and in the right place is therefore vital for health.

Despite its important role in inflammation, there is still a lot of mystery around how much IL-1β is made and how it is released from immune cells. For example, IL-1β lacks the usual molecular 'identity tag' found on many other proteins that are exported out of cells, which directs them through the usual processing pathway (*).

Recent reports have suggested that IL-1β production might be dependent on something known as the unfolded protein response (UPR) - a 'fail safe' that prevents abnormal proteins building up inside cells when they are in stressful conditions, such as low nutrient levels. But growing evidence points to a role for the UPR in producing proteins under normal conditions too.

In search of the connection between the UPR and IL-1β production, Malhotra and Marioara Chiritoiu, first author of the study, took a clue from simple slime moulds and yeast that use similar pathways to secrete proteins when they are stressed. One of the key players in this process is known as GrpA, which is very similar to a protein called GRASP55 in humans and mice.

Using genetic engineering techniques, the CRG team created mice lacking the GRASP55 gene and took a close look at their immune cells. Straight away they noticed that IL-1β was building up in clumps (aggregates) inside the cells instead of being released, meaning that it was no longer able to trigger inflammation. These aggregates are bad news, as they mean that neither IL-1β nor the immune cells in which it is produced can respond properly to inflammation triggers.

The researchers also found that another protein playing an important role in activating the UPR under times of stress, known as IRE1α, was no longer working properly in these cells.

Discovering this crucial connection between the UPR, GRASP55 and IL-1β suggests that interfering with these pathways could be a potential way to control the production and release of this inflammatory molecule.

Drugs that block the UPR are currently being developed as treatments for neurodegenerative diseases involving abnormal proteins, including Alzheimer's, Parkinson's and Huntington's, so it will be interesting to see whether this approach could also be applied for finding new anti-inflammatory therapies.

"These findings are very important for understanding how proteins like IL-1β, which are not secreted using the standard pathway, are released from cells," says Malhotra.

"It will be very interesting to find out whether GRASP55 and UPR prevent other secreted molecules from aggregating inside cells and play a more general role in controlling the quantities of proteins that are destined to be exported," concludes Chiritoiu.
-end-


Center for Genomic Regulation

Related Immune Cells Articles:

Mapping immune cells in brain tumors
It is not always possible to completely remove malignant brain tumors by surgery so that further treatment is necessary.
Nutrient deficiency in tumor cells attracts cells that suppress the immune system
A study led by IDIBELL researchers and published this week in the American journal PNAS shows that, by depriving tumor cells of glucose, they release a large number of signaling molecules.
Experience matters for immune cells
The discovery that immune T cells have a spectrum of responsiveness could shed light on how our immune system responds to infections and cancer, and what goes wrong in immune diseases.
Immune cells against Alzheimer's?
German researchers have developed a novel, experimental approach against Alzheimer's.
Arming the body's immune cells
Researchers at UC have discovered a previously unknown mechanism that could explain the reason behind decreased immune function in cancer patients and could be a new therapeutic target for immunotherapy for those with head and neck cancers.
Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.
How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.
How the immune system becomes blind to cancer cells
Researchers have described the activation of a key protein used by tumor cells to stop the body's immune response.
What protects killer immune cells from harming themselves?
White blood cells, which release a toxic potion of proteins to kill cancerous and virus-infected cells, are protected from any harm by the physical properties of their cell envelopes, find scientists from UCL and the Peter MacCallum Cancer Centre in Melbourne.
How self-reactive immune cells are allowed to develop
A research team at Lund University in Sweden has found the mechanism that controls the growth of B1-cells in mice.
More Immune Cells News and Immune Cells Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.